Revisiting clinical trial design – more adaptability in Phase I – III?
Elihu H. Estey
How to treat a previously untreated CLL patient
Treatment for older AML patients - when is an allogeneic transplant suitable?
Results of trial of vadastuximab talirine plus hypomethylating agents in AML
Factors to consider in frontline and relapsed CLL before treatment